Dr Anne-Catherine Raby

2019

• Brook, A. C.et al. 2019. Neutrophil-derived miR-223 as local biomarker of bacterial peritonitis. Scientific Reports 9, article number: 10136. (10.1038/s41598-019-46585-y)

2018

• Raby, A. and Labeta, M. 2018. Preventing peritoneal dialysis-associated fibrosis by therapeutic blunting of peritoneal toll-like receptor activity. Frontiers in Physiology 9, article number: 1692. (10.3389/fphys.2018.01692)
• Raby, A.et al. 2018. Targeting toll-like receptors with soluble toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis. Kidney International 94(2), pp. 346-362. (10.1016/j.kint.2018.03.014)

2017

• Raby, A.et al. 2017. Toll-like receptors 2 and 4 are potential therapeutic targets in peritoneal dialysis-associated fibrosis. Journal of the American Society of Nephrology 28(2), pp. 461-478. (10.1681/ASN.2015080923)
• Holst, B.et al. 2017. Soluble toll-like receptor 2 is a biomarker for sepsis in critically ill patients with multi-organ failure within 12 h of ICU admission. Intensive Care Medicine Experimental 5(1) (10.1186/s40635-016-0116-z)

2016

• Raby, A. and Labeta, M. 2016. Therapeutic boosting of the immune response: turning to CD14 for help. Current Pharmaceutical Biotechnology 17(5), pp. 414-418. (10.2174/1389201017666160114095708)

2014

• Shang, L.et al. 2014. Selective antibody intervention of toll-like receptor 4 activation through Fc γ receptor tethering. Journal of Biological Chemistry 289(22), pp. 15309-15318. (10.1074/jbc.M113.537936)

2013

• Raby, A.et al. 2013. Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Science Translational Medicine 5(185), article number: 185ra64. (10.1126/scitranslmed.3005544)

2012

• Holst, B.et al. 2012. Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a. Anaesthesia 67(1), pp. 60-64. (10.1111/j.1365-2044.2011.07011.x)

2011

• Colmont, C. S.et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
• Raby, A.et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)

2009

• Raby, A.et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)

2008

• Raby, A. 2008. Biochemical and functional study of the immunomodulatory capacity of the soluble form of human Toll-like receptor 2. PhD Thesis, Cardiff University.